Flt3 Gene Mutation clinical trials

Explore recruiting flt3 gene mutation clinical trials.

Recruiting flt3 gene mutation studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Flt3 Gene Mutation trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An open-label, phase 2 study, evaluating the efficacy of treatment with Gilteritinib in measurable residual disease eradication in patients with FLT3-ITD mutated acute myeloid leukemia

Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

HOVON 156 AML: A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy.

Lithuania, Austria, Germany, Ireland, Norway, Sweden +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined with Chemotherapy in Children, Adolescents and Young Adults with FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Spain, Italy, France, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Flt3 Gene Mutation trials by city

Flt3 Gene Mutation in Toronto Flt3 Gene Mutation in Vancouver Flt3 Gene Mutation in Montreal Flt3 Gene Mutation in Calgary Flt3 Gene Mutation in Edmonton Flt3 Gene Mutation in Ottawa Flt3 Gene Mutation in Winnipeg Flt3 Gene Mutation in Quebec City Flt3 Gene Mutation in Hamilton Flt3 Gene Mutation in Kitchener Flt3 Gene Mutation in London Flt3 Gene Mutation in Halifax Flt3 Gene Mutation in New York Flt3 Gene Mutation in Los Angeles Flt3 Gene Mutation in Chicago Flt3 Gene Mutation in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease